ResMed Inc. (NYSE:RMD) insider James Hollingshead sold 600 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $112.09, for a total transaction of $67,254.00. Following the completion of the transaction, the insider now directly owns 83,689 shares in the company, valued at approximately $9,380,700.01. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

James Hollingshead also recently made the following trade(s):

  • On Tuesday, November 27th, James Hollingshead sold 5,893 shares of ResMed stock. The stock was sold at an average price of $105.52, for a total transaction of $621,829.36.
  • On Thursday, November 1st, James Hollingshead sold 600 shares of ResMed stock. The stock was sold at an average price of $105.93, for a total transaction of $63,558.00.
  • On Monday, October 1st, James Hollingshead sold 600 shares of ResMed stock. The stock was sold at an average price of $115.88, for a total transaction of $69,528.00.

Shares of NYSE:RMD traded down $1.22 during trading on Thursday, reaching $110.91. The company had a trading volume of 63,993 shares, compared to its average volume of 798,597. The firm has a market capitalization of $15.98 billion, a price-to-earnings ratio of 31.40, a PEG ratio of 2.86 and a beta of 1.01. ResMed Inc. has a 12 month low of $83.60 and a 12 month high of $116.64. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.58 and a quick ratio of 1.91.

ResMed (NYSE:RMD) last issued its quarterly earnings results on Thursday, October 25th. The medical equipment provider reported $0.81 EPS for the quarter, topping the Zacks’ consensus estimate of $0.80 by $0.01. The firm had revenue of $588.28 million for the quarter, compared to analyst estimates of $576.66 million. ResMed had a net margin of 13.94% and a return on equity of 26.29%. As a group, equities research analysts expect that ResMed Inc. will post 3.7 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 13th. Stockholders of record on Thursday, November 8th will be paid a $0.37 dividend. The ex-dividend date of this dividend is Wednesday, November 7th. This represents a $1.48 dividend on an annualized basis and a dividend yield of 1.33%. ResMed’s dividend payout ratio (DPR) is 41.93%.

Several institutional investors have recently made changes to their positions in RMD. Harvest Fund Management Co. Ltd boosted its stake in shares of ResMed by 245.4% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 905 shares of the medical equipment provider’s stock valued at $104,000 after purchasing an additional 643 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of ResMed by 144.7% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,018 shares of the medical equipment provider’s stock valued at $117,000 after purchasing an additional 602 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of ResMed in the 2nd quarter valued at $148,000. Piedmont Investment Advisors LLC purchased a new stake in shares of ResMed in the 2nd quarter valued at $167,000. Finally, Cornerstone Wealth Management LLC purchased a new stake in shares of ResMed in the 2nd quarter valued at $167,000. 65.02% of the stock is owned by institutional investors.

A number of equities analysts have recently commented on the stock. BMO Capital Markets increased their price target on shares of ResMed from $107.00 to $109.00 and gave the stock a “market perform” rating in a report on Friday, October 26th. Credit Suisse Group raised shares of ResMed from a “neutral” rating to an “outperform” rating in a report on Friday, October 26th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $114.50.

ILLEGAL ACTIVITY WARNING: “ResMed Inc. (RMD) Insider James Hollingshead Sells 600 Shares” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/resmed-inc-rmd-insider-james-hollingshead-sells-600-shares/2665033.html.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Further Reading: Compound Interest and Why It Matters When Investing

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.